What is HC Wainwright’s Forecast for CRDL Q1 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.34) EPS.

Several other analysts have also weighed in on CRDL. raised Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price objective on shares of Cardiol Therapeutics in a report on Monday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Cardiol Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Stock Performance

Shares of NASDAQ:CRDL traded down $0.02 during trading on Tuesday, hitting $1.38. 522,206 shares of the stock were exchanged, compared to its average volume of 545,422. Cardiol Therapeutics has a 1-year low of $0.80 and a 1-year high of $1.59. The company has a market capitalization of $153.75 million, a price-to-earnings ratio of -4.91 and a beta of 0.82. The company’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.89 and a current ratio of 3.89.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04.

Institutional Trading of Cardiol Therapeutics

Several institutional investors have recently bought and sold shares of CRDL. Tejara Capital Ltd boosted its stake in Cardiol Therapeutics by 95.1% in the 4th quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock valued at $4,893,000 after buying an additional 2,500,000 shares in the last quarter. Bank of America Corp DE boosted its stake in Cardiol Therapeutics by 1,983.0% in the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after buying an additional 524,598 shares in the last quarter. Integrity Alliance LLC. acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at $416,000. Citadel Advisors LLC boosted its stake in Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after buying an additional 425,862 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Cardiol Therapeutics in the 3rd quarter valued at $249,000. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics News Summary

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $9.00 price target, and materially tightened/raised its EPS outlook — forecasting quarter-by-quarter EPS of ($0.06) and raising FY2026 to ($0.27) (from $0.41) and FY2027 to ($0.34) (from $0.51). Those upward revisions and the high price target are constructive for sentiment. MarketBeat: HC Wainwright Estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its “Buy” rating and set an $8.00 target, reiterating bullish analyst support and providing an additional near-term catalyst for buyers. Benzinga: Canaccord Reaffirmation
• Neutral Sentiment: Consensus full‑year EPS expectations remain negative (around ($0.33) per share), so despite analyst activity the company is still expected to report losses — this limits how strongly upgrades will translate to valuation changes. MarketBeat: Consensus Estimates
• Negative Sentiment: Brookline Capital Markets trimmed near-term and full‑year EPS forecasts (Q3 to ($0.08) from ($0.07), Q4 to ($0.09), and FY2026 to ($0.31) from ($0.29)), a downgrade that introduces downward pressure and highlights execution/forecast risk. MarketBeat: Brookline Estimate Cuts

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.